Skip to main content
. 2023 Nov 8;14:1297352. doi: 10.3389/fimmu.2023.1297352

Figure 5.

Figure 5

Pharmacokinetics and pharmacodynamics of narsoplimab in cynomolgus monkeys after a single IV infusion of narsoplimab. (A) Dose-dependent exposure after a single IV dose. (B) Dose-related pharmacodynamic effect. (C) Concentration-dependent pharmacodynamic effect. * % inhibition of the lectin pathway was determined ex vivo by mannan-induced C4 activation with an ELISA assay. EC50, half-maximal effective concentration; IV, intravenous.